| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Challenges and new horizons for sickle cell disease
|
The Lancet Haematology,
|
|
2018
|
5 |
2 |
p. e53
|
article
|
| 2 |
Don't judge a JAK2 inhibitor by spleen response alone
|
Mascarenhas, John
|
|
2018
|
5 |
2 |
p. e56-e57
|
article
|
| 3 |
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
|
Harrison, Claire N
|
|
2018
|
5 |
2 |
p. e73-e81
|
article
|
| 4 |
Of blood and bone: the sotatercept adventure
|
Santini, Valeria
|
|
2018
|
5 |
2 |
p. e54-e55
|
article
|
| 5 |
Revisiting WHO haemoglobin thresholds to define anaemia in clinical medicine and public health
|
Pasricha, Sant-Rayn
|
|
2018
|
5 |
2 |
p. e60-e62
|
article
|
| 6 |
Rituximab maintenance is efficacious, but is it useful?
|
O'Brien, Susan
|
|
2018
|
5 |
2 |
p. e58-e59
|
article
|
| 7 |
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study
|
Dartigeas, Caroline
|
|
2018
|
5 |
2 |
p. e82-e94
|
article
|
| 8 |
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial
|
Komrokji, Rami
|
|
2018
|
5 |
2 |
p. e63-e72
|
article
|
Journal description